Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

General Information

Summary Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.
Description This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months (± one month), beginning six months after subject completion or withdrawal from the FT500-101 study.
Clinical trials phase Other
Start date (estimated) 2019-06-11
End date (estimated) 2034-12-31
Clinical feature
Label Advanced Malignant Solid Neoplasm
Link http://purl.obolibrary.org/obo/NCIT_C129707
Description A malignant solid neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.

Administrative Information

NCT number NCT04106167
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04106167
Other study identifiers
Name FT-003
Source weblink https://clinicaltrials.gov/ct2/show/NCT04106167
Public contact
Email clinical@fatetherapeutics.com
Public email clinical@fatetherapeutics.com
First name Rebecca
Last name Reynolds
Phone +1 (0)858-875-1800
United States
Sponsors Fate Therapeutics


Which differentiated cell type is used
Label natural killer cell
Link http://purl.obolibrary.org/obo/CL_0000623
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.


Recruitment Status Recruiting
Estimated number of participants 76